Type I Interferons: Ancient Peptides with Still Under-Discovered Anti-Cancer Properties

被引：19

作者：

Caraglia, Michele ^{[1
]}

Dicitore, Alessandra ^{[2
]}

Marra, Monica ^{[1
]}

Castiglioni, Sara ^{[2
]}

Persani, Luca ^{[2
,3
]}

Sperlongano, Pasquale ^{[4
]}

Tagliaferri, Pierosandro ^{[5
]}

Abbruzzese, Alberto ^{[1
]}

Vitale, Giovanni ^{[2
,3
]}

机构：

[1] Univ Naples 2, Dept Biochem & Biophys, I-80138 Naples, Italy

[2] Ist Auxol Italiano IRCCS Milan, Milan, Italy

[3] Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy

[4] Univ Naples 2, Dept Anaesthesiol & Special Surg, I-80138 Naples, Italy

[5] Magna Graecia Univ Catanzaro, Dept Expt & Clin Med, Catanzaro, Italy

来源：

PROTEIN AND PEPTIDE LETTERS | 2013年 / 20卷 / 04期

关键词：

Type I interferons; interferon-alpha; interferon-beta; STATs; mTOR; pegylated interferons; farnesyltransferase inhibitors; EGF-R; ACTIVATED PROTEIN-KINASE; SERINE PHOSPHORYLATION; GROWTH-FACTOR; TRANSCRIPTIONAL ACTIVATION; ANTITUMOR-ACTIVITY; ADJUVANT THERAPY; HEPATITIS-C; IFN-ALPHA; APOPTOSIS; CELLS;

D O I：

10.2174/092986613805290372

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

070307 [化学生物学]; 071010 [生物化学与分子生物学];

摘要：

Type I interferons (IFNs) represent a group of cytokines that act through a common receptor composed by two chains (IFNAR-1 and IFNAR-2). Several in vitro and in vivo studies showed a potent antitumor activity induced by these cytokines. IFN-alpha, the first cytokine to be produced by recombinant DNA technology, has emerged as an important regulator of cancer cell growth and differentiation, affecting cellular communication and signal transduction pathways. IFN-alpha, is currently the most used cytokine in the treatment of cancer. However, the potential anti-tumour activity of IFN-alpha is limited by the activation of tumour resistance mechanisms. This article reviews the current knowledge about the antitumor activity of type I IFNs, focusing on new potential strategies able to strengthen the antitumor activity of these cytokines.

引用

页码：412 / 423

页数：12

共 123 条

[1]

ABBRUZZESE A, 1986, J BIOL CHEM, V261, P3085

[2]

The proteasome: structure, function, and role in the cell [J].

Adams, J .

CANCER TREATMENT REVIEWS, 2003, 29 :3-9

[3]

Ubiquitin cross-reactive protein is released by the bovine uterus in response to interferon during early pregnancy [J].

Austin, KJ ;

Ward, SK ;

Teixeira, MG ;

Dean, VC ;

Moore, DW ;

Hansen, TR .

BIOLOGY OF REPRODUCTION, 1996, 54 (03) :600-606

[4]

INTERFERON AFFECTS BOTH G1 AND S+G2 IN CELLS STIMULATED FROM QUIESCENCE TO GROWTH [J].

BALKWILL, F ;

TAYLORPAPADIMITRIOU, J .

NATURE, 1978, 274 (5673) :798-800

[5]

SHARED ARCHITECTURE OF HORMONE BINDING DOMAINS IN TYPE-I AND TYPE-II INTERFERON RECEPTORS [J].

BAZAN, JF .

CELL, 1990, 61 (05) :753-754

[6]

Human interferons alpha, beta and omega [J].

Bekisz, J ;

Schmeisser, H ;

Hernandez, J ;

Goldman, ND ;

Zoon, KC .

GROWTH FACTORS, 2004, 22 (04) :243-251

[7]

Interferons at age 50: past, current and future impact on biomedicine [J].

Borden, Ernest C. ;

Sen, Ganes C. ;

Uze, Gilles ;

Silverman, Robert H. ;

Ransohoff, Richard M. ;

Foster, Graham R. ;

Stark, George R. .

NATURE REVIEWS DRUG DISCOVERY, 2007, 6 (12) :975-990

[8]

Stat3 activation is required for cellular transformation by v-src [J].

Bromberg, JF ;

Horvath, CM ;

Besser, D ;

Lathem, WW ;

Darnell, JE .

MOLECULAR AND CELLULAR BIOLOGY, 1998, 18 (05) :2553-2558

[9]

Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-α in head and neck cancer cells in vitro and in vivo [J].

Bruzzese, F ;

Di Gennaro, E ;

Avallone, A ;

Pepe, S ;

Arra, C ;

Caraglia, M ;

Tagliaferri, P ;

Budillon, A .

CLINICAL CANCER RESEARCH, 2006, 12 (02) :617-625

[10]

Regression of basal cell carcinoma by intralesional interferon-alpha treatment is mediated by CD95 (Apo-1/Fas)-CD95 ligand-induced suicide [J].

Buechner, SA ;

Wernli, M ;

Harr, T ;

Hahn, S ;

Itin, P ;

Erb, P .

JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (11) :2691-2696

← 1 2 3 4 5 6 7 8 9 10 →